Two-Tier Lyme Testing What It Is, Why It Was Designed That Way, and Where It Fails

Few corners of Lyme medicine generate more disagreement than its laboratory test. The Tick-Borne Disease Working Group's 2022 diagnostics subcommittee wrote that "Widespread agreement exists that the currently approved gold standard test (two-tier serology) is not good enough" (HHS 2022). The 2020 IDSA–AAN–ACR clinical guideline describes the same test as "highly sensitive in patients with common extracutaneous manifestations that develop weeks to months after initial infection" (IDSA 2020), and as "highly specific when performed and interpreted according to current guidelines" (IDSA 2020). Both statements sit inside the same body of evidence, reconciled mostly by what stage of Lyme disease each author has in view and by whether the test is being judged as a clinical tool or a surveillance tool.

What the protocol is

The CDC Tickborne Diseases Reference Manual states the clinical recommendation in a sentence: "Two-step serologic testing is recommended using validated first- and second-tier tests according to a standard or modified two-test algorithm" (CDC 2022). The 2022 TBDWG diagnostics subcommittee enumerates the two algorithms currently accepted: "the two-tier test, consisting of an ELISA with confirmatory western blot" (HHS 2022), and "the modified two-tier test, consisting of a multi-antigen ELISA followed by a single antigen (C6) or other multi-antigen ELISA" (HHS 2022). The ASM 2019 review fills in the mechanics: "Standard two-tier testing (STTT) consists of an initial enzyme immunoassay (EIA) or a chemiluminescence immunoassay (CIA)" (ASM 2019) "followed by Western blot testing if the initial results show reactivity or are equivocal" (ASM 2019). Why standard ELISA misses early-stage cases is the primary failure point within this protocol.

In 2019 an alternative was cleared: "The FDA recently cleared a modified two-tier testing (MTTT) algorithm as an alternative to STTT" (ASM 2019) — two EIAs run in sequence or concurrently, with the Western immunoblot removed. The same review argues "MTTT is an improvement compared with STTT, which is less sensitive for detecting early infections, more subjective to interpret, and more labor-intensive" (ASM 2019).

The IDSA 2020 guideline emphasizes the pair-design: "Serologic tests are intended for use in 2-tiered testing protocols, rather than as stand-alone assays, as this improves specificity" (IDSA 2020); "Predictive value is increased when results are correlated with clinical features, patient history and risk factors" (IDSA 2020).

Both algorithms share a structural property a 2012 House hearing surfaced plainly: the test "does not directly detect Lyme bacteria" (House 2012) but instead "looks to see if the patient's immune system has developed antibodies against the bacteria" (House 2012). Reading the immune response rather than the pathogen is the mechanism behind most of the performance debates that follow.

How it was designed

The protocol emerged from a 1994 meeting. The 2018 HHS Tick-Borne Disease Working Group Report to Congress describes its adoption:

"The two-tiered system was adopted at the 1994 Dearborn, Michigan, meeting, which was cosponsored by FDA, NIH, CSTE, the National Committee for Clinical Laboratory Standards (NCCLS), and sponsored by laboratory directors, the state health department, and CDC. It was announced at the meeting that the two-tiered testing system would be part of the surveillance case definition for Lyme disease. A number of experts at the meeting disagreed with the decision because they felt the narrow definition would miss many patients, especially with the unexpected exclusion of some specific bands from the Lyme disease western blot test, bands most likely related to the development of a Lyme disease vaccine." — HHS, 2018, pp. 44–45. Tick-Borne Disease Workin...

The same TBDWG report describes the migration into clinical practice: "Health care professionals soon began using the two-tiered surveillance testing criteria in the clinical setting to diagnose patients" (HHS 2018). IDSA's 2006 treatment guideline, per the same report, ended up "formally transforming a testing protocol intended for surveillance into a diagnostic protocol for use in the clinical setting" (HHS 2018).

CDC itself distinguishes between those two uses. The 2018 TBDWG report quotes CDC's own definition of what a surveillance case definition is:

"The Lyme disease surveillance case definition is frequently misunderstood and misused throughout the medical community. According to CDC, a surveillance case definition is “a set of uniform criteria used to define a disease for public health surveillance… [and is] not intended to be used by health care providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs” (Centers for Disease Control and Prevention, 2017)." — HHS, 2018, pp. 22–23. Tick-Borne Disease Workin...

Where it performs well and where it doesn't

The 2020 IDSA–AAN–ACR guideline is explicit that test sensitivity depends on what stage of Lyme disease is being tested. "Most patients with a single erythema migrans skin lesion are seronegative at the time of initial presentation. Among untreated patients with microbiologically confirmed, solitary erythema migrans lesions, as few as 20% are seropositive using conventional 2-tiered antibody testing" (IDSA 2020), with sensitivity "reaching 86% in the 4th week of illness or in patients presenting with multiple erythema migrans skin lesions" (IDSA 2020). In a study cited by the same guideline: "The least sensitive method was conventional 2-tiered antibody testing performed on acute-phase serum samples (40.4%)" (IDSA 2020).

Given that early-stage sensitivity, the IDSA guideline's recommendation for a classic EM rash is categorical: "In patients with potential tick exposure in a Lyme disease endemic area who have 1 or more skin lesions compatible with erythema migrans, we recommend clinical diagnosis rather than laboratory testing" (IDSA 2020).

The picture reverses at later stages. For Lyme arthritis, IDSA reports "the sensitivity of serum antibody testing in the diagnosis of Lyme arthritis, using conventional 2-tiered testing with Western immunoblotting, is very high—in the range of 95–100%" (IDSA 2020). For early Lyme neuroborreliosis, "most patients with early Lyme neuroborreliosis are seropositive by conventional 2-tiered testing at the time of initial clinical presentation" (IDSA 2020). The test's sensitivity is a curve, not a single number.

The IDSA guideline locates the biological cause in antibody kinetics: "Results can be falsely negative in the first days to weeks following initial exposure because a detectable antibody response takes time to develop" (IDSA 2020). "This is often the case in patients with erythema migrans, an early manifestation of Lyme disease, who are tested <2 weeks after the development of the skin lesion" (IDSA 2020). Congressional testimony in 2012 described the same phenomenon in patient-facing terms — "it can take a Lyme patient 3 weeks or more after its infection with Lyme disease bacteria for the immune system to develop enough to test positive" (House 2012).

Patient-population sensitivity varies within stage as well. The 2024 HHS scoping review summarizes a pediatric study in which, in children with an EM lesion, two-tier serology had "higher sensitivity in children with multiple lesions (76.8%) compared to those with a single lesion (38.1%)" (HHS 2024). The same review also summarizes a head-to-head comparison of standard versus modified two-tier testing: "Modified testing displayed greater sensitivity to early infections, but was insufficiently sensitive to identify other Borrelia infections" (HHS 2024).

A 2012 House hearing raised a separate kind of performance failure — inter-laboratory variation:

"The interpretation of the two-tiered test results can be subjective, with essentially the same test from the same patient being performed by two separate labs reporting opposite results." — House, 2012. Global Challenges in Diag...

Surveillance test, clinical test

A load-bearing disagreement is whether the two-tier protocol should be used as a clinical diagnostic at all. The 2022 TBDWG Access to Care subcommittee frames the concern:

"The mistaken practice of applying Lyme disease surveillance case criteria as diagnostic criteria may be a barrier that prevents certain patient populations from being accurately and promptly diagnosed and treated (Bacon et al., 2003; Dressler et al., 1993; Hilton et al., 1996; Sivak et al., 1996). Surveillance case definitions are epidemiologic tools that standardize data collection in order to identify risk and track trends at a population level. Disease tracking necessitates the use of narrow inclusion criteria to avoid including “non-disease” cases, which could skew the data and result in faulty conclusions. Therefore, surveillance case criteria are not intended to identify all actual cases of an illness (Mead, 2004). With regard to Lyme disease, the erythema migrans (EM) rash is the most recognizable sign of the infection; yet, as discussed below, it may be an unreliable marker in some patient populations. The 5 cm size cut-off for the rash required by the surveillance case definition may exclude others. Similarly, the serologic criteria selected for the surveillance case definition may not be clinically appropriate for all patients." — HHS, 2022. Access to Care and Educat...

The 2018 TBDWG report underlines the mechanical consequence for reported case counts: "Under-reporting is a common phenomenon for most high-incidence diseases, and Lyme disease under-reporting is further complicated by a surveillance case definition that requires both laboratory and supportive clinical data for confirmation of all but the earliest manifestations of the illness" (HHS 2018).

Clinicians themselves report the protocol as a source of confusion. A 2021 review in Ticks and Tick-borne Diseases found that "ordering and interpreting the two-tiered serology for LD diagnosis can cause confusion for HCPs" (TTBD 2021). A 2022 MDPI survey of clinicians asked them to name their top reasons for diagnostic delay; the list included "False negative lab test (61%)" (MDPI 2022) among the top three. When clinicians rely on negative two-tier results to dismiss patient concerns, navigating doctor dismissal and advocating for testing becomes a separate clinical-encounter challenge. The 2022 TBDWG Access to Care subcommittee puts the biological challenge behind that statistic succinctly: "antibody responses in a specific individual are unpredictable and may not fall within established laboratory norms" (HHS 2022).

The 2018 TBDWG Report to Congress places testing squarely inside a broader diagnostic problem: "the limitations of the tests, coupled with scientific uncertainty and gaps in knowledge and education about how to use them, frequently result in misdiagnosed tick-borne diseases" (HHS 2018). This article focuses on two-tier protocol design and its specific failure modes; the broader landscape of why Lyme diagnostic testing fails encompasses additional factors beyond the two-tier architecture itself.

The positions, in their own voices

The 2018 TBDWG report characterized the field as "divided into two schools of thought" (HHS 2018). Each reads the same performance data differently.

The IDSA position. From the 2020 guideline: "Based on performance characteristics and practical considerations, antibody tests are first-line for the laboratory diagnosis of Lyme disease" (IDSA 2020), and IgG seronegativity in an untreated patient with months to years of symptoms "essentially rules out the diagnosis of Lyme disease" (IDSA 2020). Per the 2018 TBDWG summary, IDSA guidelines "confirm the diagnosis by two-tiered serological testing" (HHS 2018), except in cases of early Lyme disease with the EM rash.

The ILADS position, as reported in the same TBDWG summary, departs at this point — ILADS guidelines "promote the use of clinical judgment with an emphasis on both signs and symptoms of disease" (HHS 2018) rather than treating the two-tier result as the gatekeeper.

The federal-review position converges on diagnostic reform. The TBDWG's 2022 diagnostics subcommittee wrote that the test's "lack of sensitivity in early infection is well established" (HHS 2022), and that "Given the limited sensitivity of the goldstandard diagnostic test for Lyme disease, the two-tier serologic test, new diagnostic tests are critically needed" (HHS 2022). The 2024 HHS scoping review notes that when an EM rash is absent, "a Lyme disease diagnosis requires positive two-tier serologic testing (standard or modified)" (HHS 2024), with the consequence that "Clinicians, therefore, must make treatment decisions prior to receiving the test results" (HHS 2024). The IDSA 2020 guideline itself concedes that alternatives to serology remain limited — "few nonserologic testing methods are useful or practical for clinical diagnosis" (IDSA 2020), though PCR, IGeneX, and Western blot variations represent emerging options when standard two-tier testing fails.

The European position, from an ECDC expert consultation, stresses interpretation over replacement: "Current laboratory tests for Lyme borreliosis are vastly better than the prototype tests of 20–30 years ago. The currently available tests are reasonably accurate, provided that they are correctly applied and their limitations understood" (ECDC 2011). A companion caveat: "In recent years there has been a tendency for ’tests for Lyme disease’ to be included as part of a broad serological investigation panel without adequate consideration of its appropriateness in the individual patient’s case. Indiscriminate testing can lead to misleading results" (ECDC 2011).

The patient-advocacy position treats the test as the focal point of the dispute. The 2021 Nesgos review cataloged that the controversy includes the "reliability of two-tiered serologic testing to diagnose LD in early infection as compared with later stages of disease" (TTBD 2021). A 2012 Senate hearing preserved a counter-voice on the opposite risk: "Over-diagnosis of Lyme disease, may lead to a dangerous under-diagnosis of other conditions and over treatment with antibiotics" (Senate 2012). "Chronic Lyme disease cannot be diagnosed based on clinical symptoms solely" (Senate 2012).

Downstream effects

Downstream effects have been documented. The 2024 HHS scoping review cited a pediatric study in which "13.9% of children who tested positive for Lyme disease using the standard two-tier Lyme disease test were not initially treated with an appropriate antibiotic" (HHS 2024). A 2014 PeerJ survey of patients with persistent symptoms reported the diagnostic paths of its respondents — "diagnosed by EM rash (6.3%), CDC-positive two-tier test result (ELISA and Western blot, 29.7%)" (PeerJ 2014), with the remainder falling outside the CDC-positive envelope.

A further complication, flagged in the 2018 TBDWG report: newly recognized Borrelia variants "may not be detected by standard two-tiered testing for Lyme disease" (HHS 2018). This article focuses on Lyme two-tier testing specifically; testing protocols for other tick-borne diseases are a separate matter.

A 2014 BMC Family Medicine paper documents the opposite failure mode — patients diagnosed with chronic Lyme disease "based on nonstandard interpretations of serology or other testing that has little or no validity, or based on clinical symptoms alone" (BMC 2014).

A different limit applies on the back end. The IDSA 2020 guideline notes that "In a seropositive patient, it can be difficult to determine whether antibody reactivity is due to past infection versus active/current infection" (IDSA 2020) because "both IgM and IgG *B. burgdorferi-*specific antibody responses can persist for years or even decades after the infection has been eradicated" (IDSA 2020). A 2022 Johns Hopkins prospective cohort study adds that "Even B. burgdorferi antibody levels are not specific or sensitive in the post-treatment period and are not included in the IDSA proposed case definition" (JHU 2022).

Where the debate is actually going

The convergence across CDC, IDSA, and TBDWG voices surveyed here is narrower than the public debate suggests. Each acknowledges poor early-infection sensitivity. Each acknowledges the protocol's surveillance origin. The 2022 TBDWG subcommittee itself agrees that "Many advanced diagnostic testing platforms are already showing improvement over two-tier testing" (HHS 2022), though "there may never be a single one-size-fits-all test developed to diagnose Lyme disease and associated TBDs" (HHS 2022). What positions disagree on is how much clinical weight to give a negative two-tier result in a symptomatic patient, how much weight to give clinical judgment when the test is negative, and whether the surveillance-to-clinical migration was legitimate. Those are the live questions. The performance numbers themselves are, at this point, largely shared.

Sources

    Not medical advice. See a healthcare provider for medical decisions. Medical Disclaimer